Update information

Update information

June 2022: We have reviewed the evidence and made new recommendations on diagnosis, information and support, coordination of care and symptom management and rehabilitation. These recommendations are marked [2022].

We have also made some changes without an evidence review:

  • Online resources were added to recommendation 1.2.1 to reflect current information provision.

  • Health and social care professionals who may be part of a multiple sclerosis (MS) multidisciplinary team were added to recommendation 1.3.2 to reflect current practice.

  • Recommendation 1.4.2 was amended to reflect current evidence on the effects of smoking on progression of disability.

  • Links were added to current guidance on vaccination in recommendation 1.4.3.

  • Recommendation 1.5.21 was amended to reflect that referral to a physiotherapist with expertise in MS may be an option, in line with current practice.

  • Changes were made to recommendation 1.6.3 to include assessing progression and active disease, discussion of whether disease-modifying treatments are appropriate, and documenting disability as part of a comprehensive review. Examples were added to assessment of employment.

  • A link was added to include young carers assessments in recommendation 1.6.9.

  • Recommendation 1.7.18 was updated to include consideration of disease-modifying treatments after a relapse, in line with current practice.

These recommendations are marked [2014 amended 2022].

Recommendations marked [2014] last had an evidence review in 2014. In some cases, minor changes have been made to the wording to bring the language and style up to date, without changing the meaning.

November 2019: Recommendation 1.5.32 on the use of Sativex (a THC:CBD spray) to treat spasticity in people with MS has been replaced with a cross-reference to recommendations on THC:CBD spray in the NICE guideline on cannabis-based medicinal products.

ISBN: 978-1-4731-4607-5